To address the major challenge of understanding the clinical relevance of the increasingly available large amount of tumour genomic data in BC. Methods Histologically reviewed, paraffin tumour DNA samples (N = 1092) from patients who had received anthracycline-based adjuvant chemotherapy in the frame of two randomized trials by HeCOG (HE10/00, pre-trastuzumab; HE10/05, post-trastuzumab era), were investigated with targeted massively parallel sequencing (Ion Torrent systems) for variants in 58 genes implicated in BC. Upon multiple stringent quality filters, pathogenic mutations (mut) and allelic imbalance (AI) were evaluable in 844 cases (77.3%). IHC4 was used for BC subtyping. Results Mut were observed in 499 and AI in 497 tumors (59%), reaching up to 55 and 20 affected genes in single tumours, respectively. Mut and AI often coexisted (p < 0.0001), while AI was positively related to nodal status (p = 0.0241). Mut were more frequent in TP53 (25%, excluding non-pathogenic p.P72R), PIK3CA (24.6%), GATA3 (8.8%), CDH1 (6.3%), MLL3 (5.5%), ARID1B (5.1%), TBX3 (5.1%) and PTEN (4.7%), while AI in EGFR (51.2%), TERT (41.4%), TP53 (40.8%), CASP8 (33.5), PARP2 (32.5%), GATA3 (28.9%), and BRCA1 (22.2%). TP53mut were more frequent in triple-negative and HER2-enriched BC (45% each), while PIK3CAmut (32%) in luminal A tumours (p < 0.0001). In luminal HER2-negative tumours, TP53mut were significantly associated with shorter disease-free survival (DFS) (log-rank, p = 0.0032), aggravating the prognosis of patients with any nodal status (p < 0.0001), irrespectively of Ki67 status that was used for distinguishing between luminal A and B subtypes. In these luminal HER2-negative tumours, AI in less than 6 genes in the presence of PIK3CAmut conferred the longest, while AI in more than 6 genes in the absence of PIK3CAmut the shortest DFS (p = 0.0156); this AI/PIK3CAmut combination was associated with worse prognosis in patients with 0-3 positive nodes, which fared similarly to those with higher nodal involvement (p < 0.0001).
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The 12-gene DCIS Score has been validated to predict 10yr risk of local recurrence (DCIS or invasive) (Solin et al, JNCI, 2013) . Here we report the Clinical Laboratory experience in the first 2 yrs of assay availability for the score results, quantitative gene expression and results of the assay across histologic subtypes. Methods 3045 patient (pt) samples from 12/11 to 1/14 were processed for DCIS score. The DCIS score is based on the validated algorithm using 7 of 16 cancer-related genes from the 21-gene assay. Low, intermediate, and high risk groups are defined as scores of <39, 39-54, and ≥55, respectively. Descriptive statistics for the score and single gene values for ER, PR, and HER2 were used. Positive cutoffs: ≥6.5 for ER; ≥5.5 for PR, and for HER2, ≥11.5 is positive, equivocal is 10.7 to 11.4, < 10.7 is negative. Results Of 3045 samples, 2264 (74%) were excisions and 781 (26%) were cores; median age was 60y (21-94). The mean DCIS Score was 29 (0-97) with a mean score result of 29 for excisions and 29 for cores. 2064 (68%) were low, 495 (16%) were intermediate, and 486 (16%) were high. Mean ER, PR, and HER2 levels were 9.6, 7.5, and 9.9, respectively, and similar between excisions and cores. A range of DCIS Score results were observed for each histologic subtype with the highest mean values observed in samples with >50% comedo necrosis (mean = 47) and solid (mean = 34) subtypes, although none of the scores were in the high risk category. Aim ABCSG-32 was designed to evaluate the cardiac toxicity of bevacizumab (B) and non-pegylated liposomal doxorubicin (N) when added to docetaxel + trastuzumab (DH) in the neoadjuvant treatment of early, HER2-positive breast cancer (BC) within a randomized phase II trial. Secondary aims were to evaluate the non-cardiac safety and the efficacy of the 4 drug combinations as measured by the rates of pathological complete responses (pCR). Methods 100 patients (pts) with biopsy-proven, invasive, early, HER2-pos breast cancer were stratified according to major risk factors including estrogen-receptor-status, histology, grading, and center and were randomized to receive 6 cycles (q 21 days) of either D100 mg/m + H8/6 mg/kg (DH, n = 25), DH + B15 mg/kg (DHB, n = 25), D75H + N 2 50 mg/m (DHN, n = 26), or D75HN + B 15 mg/m (DHNB, n = 24). All pts received 2 2 pegfilgrastim 6 mg sc on day 2. Left ventricular (LV) ejection fraction (EF) was measured at baseline, before each treatment cycle, and before sugery. A cardiac toxicity event (CTE) was defined as the occurrence of either symptomatic LV dysfunction NYHA II-IV, or an asymptomatic drop of EF (adEF) of >15% from baseline, or an adEF <50%, or the appearance of significant arrhythmias requiring treatment. The trial was designed to detect a difference in the incidence of CTE of 8% in the control group (DH) vs. 44% in each of the experimental groups (power: 80%, two-sided alpha: 0.05). Results Cardiac toxicity was low with a CTE in only 3 pts (DH: 0, DHB: 1, DHN: 1, DHNB: 1). Non-cardiac toxicity/patient as evaluated by the incidence of serious adverse events (SAE, n = 50) and significant safety events (SSE, n = 114) was acceptable (SAE (Kassel, Germany) N. Burchardi (Neu-Isenburg, Germany) S. Loibl (Neu-Isenburg, Germany) G. Von Minckwitz (Neu-Isenburg, Germany) V. Möbus (Frankfurt, Germany) Aim Combined chemotherapy requires compromises in terms of dosage and treatment interval due to toxicities. The sequential administration of monotherapies allows high doses of single substances and dose-dense intervals. So far, such regimens have proved to be very effective in early breast cancer with high risk of recurrence. Nab-paclitaxel (nP) leads to a more favorable toxicity profile and greater efficacy compared with solvent-based taxanes. Methods The GAIN2 study compares toxicity and efficacy of a pre-defined dose-dense high-dose regimen (EnPC) with a dose-dense regimen, where single doses are adjusted depending on individual haematological and non-haematological toxicities (dtEC-dtD). Primary endpoint is the invasive disease-free survival in patients with primary node-positive or high-risk node-negative breast cancer. Two safety interim analyses after 200 and 900 patients who have completed chemotherapy are planned. The results of the first safety analysis will be presented. In addition to the standard analyses for haematological and non-haematological toxicities, any affections of the cranial nerves as well as the rate of macular degeneration and anaphylactic reactions are of special interest. Results
In terms of hematological adverse events, the rate of febrile neutropenia grade 3-4 (14% vs. 5%) and thrombocytopenia grade 3-4 (14% vs. 5%) was significantly increased in the EnPC arm. As for the non-haematological side effects, there were significantly more patients developing anorexia (grade 1-4) in the EnPC arm. There were no differences between the treatment arms for the toxicities of special interest. In the EnPC arm, 28% required dose-reductions due to hematological toxicities compared with only 11% in the dtEC dtD arm (p = 0.002). The dose could be escalated to the maximum in half of the patients receiving dtEC dtD. In 7% of women a reduction was required in the 4th cycle of docetaxel. Conclusions Due to similar toxicity profiles, the study will be continued without changes. 
The BIG 2-98 is a randomized phase III trial that tested the effect of adding docetaxel with anthracycline-based adjuvant chemotherapy (CT) in women with node-positive breast cancer (BC). here we present the 10 year safety and efficacy analyses and report an exploratory analysis of the predictive value of Ki67 for docetaxel efficacy. Methods In total, 2,887 patients with node positive BC were randomly assigned to one of four treatments: (I) sequential control: doxorubicin (A, 75 mg/m2) × 4 → CMF; (II) concurrent control: AC × 4 → CMF; (III) A × 3 → docetaxel (T, 100 mg/m2) × 3 → CMF and (IV) : AT (50/75 mg/m2) × 4 → CMF. The primary objective was to evaluate the efficacy of docetaxel regardless of the schedule on disease free survival (DFS). Secondary objectives were toxicity, DFS between sequential arms and concurrent arms, and overall survival (OS). Ki67 expression was centrally evaluated by immunohistochemistry. Tumours with Ki67 ≥14% were considered to have a high proliferation index. Results After a median follow-up 10.1 years (max 12.9 years) and 1,072 DFS events, docetaxel treatment did not improve DFS or OS compared to control arms (DFS: HR = 0.91, 95% CI = 0.81-1.04; P = 0.16; OS: HR = 0.88, 95% CI = 0.76-1.03; P = 0.11). Similar results were obtained in secondary comparisons where sequential docetaxel was compared with sequential control (DFS: HR = 0.86, 95% CI = 0.72-1.03, P = 0.1; OS: HR = 0.85, 95% CI = 0.68-1.06; P = 0.15) or with concurrent doxorubicin-docetaxel (DFS: HR = 0.88, 95% CI = 0.7-1.01; P = 0.09; OS: HR = 0.84, 95% CI = 0.7-1.01; P = 0.06). Worsening or development of treatment-related neurotoxicity following completion of adjuvant chemotherapy occurred in 1.6% and 1% of patients in the docetaxel and non-docetaxel-based regimens, respectively 
